• 1
    Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. Human NK-cell receptors. Immunol Today 2000;21: 4202.
  • 2
    Houchins JP, Lanier LL, Niemi E, Phillips JH, Ryan JC. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. J Immunol 1997;158: 36039.
  • 3
    Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, Bottino C, Moretta L. Existence of both inhibitory (p58) and activitory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995;182: 87584.
  • 4
    Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998;188: 95360.
  • 5
    Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, Moretta L, Moretta A. p46, a novel natural killer cell-specific surface molecule which mediates cell activation. J Exp Med 1997;186: 112936.
  • 6
    Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A. Recognition of hemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001;409: 105560.
  • 7
    Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, et al. Identification and molecular characterization of NKp30 a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190: 150516.
  • 8
    Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni A. NKp44 a triggering receptor involved in tumor cell lysis by activated human natural killer cells is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189: 78796.
  • 9
    Vitale M, Falco M, Castriconi R, Parolini S, Zambello R, Semenzato G, Biassoni R, Bottino C, Moretta L, Moretta A. Identification of NKp80 a novel triggering molecule expressed by human NK cells. Eur J Immunol 2001;31: 23342.
  • 10
    Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK Cells and T Cells by NKG2D a receptor for stress-inducible MICA. Science 1999;285: 7279.
  • 11
    Wu J, Song Y, Bakker ABH, Bauer S, Spies T, Lanier LL, Phillips JH. An activating immuno receptor complex formed by NKG2D and DAP10. Science 1999;285: 7302.
  • 12
    Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. 2001. ULBPs novel MHC Class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14: 12333.
  • 13
    Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Mullberg J, Rousseau A.M, Ulrich D, Armitage R. ULBP 123: novel MHC Class I-related molecules that bind to human cytomegalovirus glycoprotein UL16 activate NK cells. Eur J Immunol 2001;31: 142837.
  • 14
    Radaev S, Rostro B, Brooks AG, Colonna M, Sun PD. Conformational plasticity revealed by the co-crystal structure of NKG2D and its Class I MHC-like ligand ULBP3. Immunity 2001;15: 103949.
  • 15
    Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins novel MHC Class I-related proteins bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002;168: 6718.
  • 16
    Groh V, Barham S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex Class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996;93: 1244550.
  • 17
    Li P, Sirkku TW, Bauer S, Morris DL, Spies T, Strong RK. Crystal structure of the MHC Class I homolog MIC-A a γδ T cell ligand. Immunity 1999;10: 57784.
  • 18
    Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC Class I-like ligand MICA. Nat Immunol 2001;2: 44351.
  • 19
    Bahram S. MIC genes: from genetics to biology. Adv Immunol 2000;76: 160.
  • 20
    Bahram S, Bresnahan M, Geraghty DE, Spies TA. A second lineage of mammalian major histocompatibility complex Class I genes. Proc Natl Acad Sci USA 1994;91: 625963.
  • 21
    Stephens HA. MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol 2001;22: 37885.
  • 22
    Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96: 687984.
  • 23
    Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001;31: 107686.
  • 24
    Lanier L, Phillips J. Inhibitory MHC Class I receptors on NK cells and T cells. Immunol Today 1996;17: 8691.
  • 25
    Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M. Paired inhibitory and triggering NK cell receptors for HLA Class I molecules. Hum Immunol 2000;61: 717.
  • 26
    Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ. HLA-E binds to natural killer cell receptors CD94/NKG2A B and C. Nature 1998;391: 7959.
  • 27
    Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998;95: 5199204.
  • 28
    Colonna M, Navarro F, Bellon T, Llano M, Samaridis J, Angman L, Cella M, Lopez-Botet M. A common inhibitory receptor for major histocompatibility complex Class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997;186: 180918.
  • 29
    Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu M-L. A novel immunoglobulin superfamily receptor for cellular and viral MHC Class I molecules. Immunity 1997;7: 27382.
  • 30
    Paul P, Adrian Cabestre F, Le Gal F-A, Khalil-Daher I, Le Danff C, Schmid M, Mercier S, Avril M.-F, Dausset J, Guillet J-G, Carosella ED. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 1999;59: 195460.
  • 31
    Wagner SN, Rebman V, Willers CP, Grosse-Wilde H, Goos M. Expression analysis of classic and non-classic HLA molecules before interferon ala-2b treatment of melanoma. Lancet 2000;356: 2201.
  • 32
    Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 2001;92: 36976.
  • 33
    Carosella ED, Paul P, Moreau P, Rouas-Freiss N. HLA-G and HLA-E: fundamental and pathophysiological aspects. Immunol Today 2000;21: 5324.
  • 34
    Ibrahim E, Guerra N, Lacombe M, Angevin E, Chouaib S, Carosella ED, Caignard A, Paul P. Tumor-specific upregulation of the nonclassical Class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001;261: 683845.
  • 35
    Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein upregulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T cell lymphomas and indolent B cell lymphomas. Blood 2002;99: 60917.
  • 36
    Urosevic M, Kurrer M, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A. Human leukocyte antigen G upregulation in lung cancer associates with high-grade histology human leukocyte antigen Class I loss and interleukin-10 production. Am J Pathol 2001;159: 81724.
  • 37
    Fukushima Y, Oshika Y, Nakamura M, Tokunaga T, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Ueyama Y, Tamaoki N. Increased expression of human histocompatibility leucocyte antigen-G in colorectal cancer cells. Int J Mol Med 1998;2: 34951.
  • 38
    Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A Class I antigen HLA-G expressed in human trophoblasts. Science 1990;248: 2203.
  • 39
    Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the Class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997;186: 28998.
  • 40
    Le Gal F-A, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet J-G, Carosella ED, Rouas-Freiss N. HLA-G mediated-inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999;11: 13516.
  • 41
    Riteau B, Menier C, Khalil-Daher I, Sedlik C, Dausset J, Rouas-Freiss N, Carosella ED. HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol 1999;43: 20311.
  • 42
    Rajagopalan S, Long EO. A human histocompatibility leucocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999;189: 10939.
  • 43
    Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, Vitale C, Bertone S, Moretta A, Moretta L, Mingari MC. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49 an HLA-G1-specific receptor. Proc Natl Acad Sci USA 1999;96: 56749.
  • 44
    Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules coexpressed on target cells. Eur J Immunol 1999;29: 27783.
  • 45
    Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED. HLA-G2 -G3 and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001;166: 5018–26.
  • 46
    Rouas-Freiss N, Marchal-Bras Goncalves R, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997; 94: 115205.
  • 47
    Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Anne Le Gal F, Avril MF, Dausset J, Guillet JG, Carosella ED. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 45105.
  • 48
    Paul P, Rouas-Freiss N, Moreau P, Adrian Cabestre F, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, Morales P, Arnaiz-Villena A, et al. HLA-G -E -F preworkshop: tools and protocols for analysis of non classical Class I genes transcription and protein expression. Hum Immunol 2000;61: 117795.
  • 49
    Robertson MJ, Cochran KJ, Cameron C, Le J-M, Tantravahi R, Ritz J. Characterization of a cell line NKL derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996;24: 40615.
  • 50
    Menier C, Riteau B, Dausset J, Carosella ED, Rouas-Freiss N. HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival. Hum Immunol 2000;61: 111825.
  • 51
    Lee N, Malacko AR, Ishitani A, Chen MC, Bajorath J, Marquardt H, Geraghty DE. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 1995;3: 591600.
  • 52
    Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The α1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA 1997; 94:524954.
  • 53
    Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J, Carosella ED, Rouas-Freiss N. HLA-G1 coexpression boosts the HLA Class I-mediated NK lysis inhibition. Int Immunol 2001;13: 193201.
  • 54
    Burt D, Johnston D, Rinke De Wit T, Van Den Elsen P, Stern PL. Cellular immune recognition of HLA-G expressing choriocarcinoma cell line JEG-3. Int J Cancer 1991;6: 11722.
  • 55
    Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells fibroblasts keratinocytes and monocytes. Human Immunol 1999;60: 32330.
  • 56
    Bjorkman PJ, Parham P. Structure function and diversity of Class I major histocompatibility complex molecules. Annu Rev Immunol 1990;59: 25388.
  • 57
    Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T Cells. Science 1998;279: 173740.
  • 58
    Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8αβT cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001;2: 25560.
  • 59
    Rajagopalan S, Fu J, Long EO. Induction of IFN-γ production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting cells. J Immunol 2001;167: 187781.
  • 60
    Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA Class I phenotypes in human tumors. Immunol Today 1997;18: 8995.
  • 61
    Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000;21: 45564.
  • 62
    Maeurer M, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT. Tumor escape from immune recognition. J Clin Invest 1996;98: 163341.
  • 63
    Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JI. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997;18: 4937.
  • 64
    Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC, Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor escape. Science 1996;274: 13636.
  • 65
    Murray MJ, Lessey BA. Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. Semin Reprod Endocrinol 1999;17: 27590.
  • 66
    Sivori S, Parolini S, Marcenaro E, Millo R, Bottino C, Moretta A. Triggering receptors involved in natural killer cell-mediated cytotoxicity against choriocarcinoma cell lines. Hum Immunol 2000;61: 10558.
  • 67
    Zwirner NW, Marcos CY, Mirbaha F, Zou Y, Stastny P. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol 2000;61: 91724.
  • 68
    Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED. Implication of HLA-G molecule in heart-graft acceptance. Lancet 2000; 355: 2138.
  • 69
    Tay GK, Hui J, Gaudieri S, Schmitt-Egenolf M, Martinez OP, Leelayuwat C, Williamson JF, Eiermann TH, Dawkins RL. PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis. Clin Exp Immunol 2000;119: 5538.
  • 70
    Choi HB, Han H, Youn JI, Kim TY, Kim TG. MICA 5.1 allele is a susceptibility marker for psoriasis in the Korean population. Tissue Antigens 2000;56: 54850.
  • 71
    Christophers E, Mrowietz U. The inflammatory infiltrate in psoriasis. Clin Dermatol 1995;13: 1315.
  • 72
    Aractingi S, Briand N, Le Danff C, Viguier M, Bachelez H, Dubertret L, Carosella ED, HLA-G and NK receptor are expressed in psoriaticskin: a possible pathway for regulating infiltrating T cells? Am JPathol, 2001; 159:717.